Adjuvant TKIs May Improve Disease-free Survival of Patients With NSCLC Post-resection

Share this content:
EGFR TKIs may improve disease-free survival of patients with NSCLC.
EGFR TKIs may improve disease-free survival of patients with NSCLC.

Adjuvant treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) may improve disease-free survival and decrease the likelihood of distant metastasis for patients with EGFR-mutant non-small cell lung cancer (NSCLC) undergoing complete tumor resection, according to a study published in the journal Chest.1

Researchers conducted a meta-analysis to determine whether the use of EGFR TKIs could improve outcomes of patients undergoing complete resection by analyzing data from 1960 patients included in 5 studies. Adjuvant TKI therapy was associated with a significant improvement in disease-free survival (hazard ratio [HR], 0.63; 95% CI, 0.41-0.99), corresponding to a 3-year absolute benefit of 3.1%.

It was found that patients who participated in studies with more than an 18-month median treatment duration experienced superior survival benefit.

For patients with EGFR mutations, the risk of relapse after treatment completion was 52% lower with adjuvant TKI therapy, compared with those that did not receive a TKI (HR, 0.48; 95% CI, 0.36-0.65). This improvement translates to a 3-year absolute benefit of 9.5%.

RELATED: FDA Approves First Liquid Biopsy Test for EGFR Mutations in Non-small Cell Lung Cancer (NSCLC)

Adjuvant TKI therapy was associated with a reduced risk of distant metastasis (odds ratio, 0.71; 95% CI, 0.56-0.92), but only a marginally significant benefit for overall survival (HR, 0.72; 95% CI, 0.49-1.06).

More than forty-two percent (95% CI, 39.1-45.6) of patients treated with an EGFR TKI in the adjuvant setting experienced grade 3 or worse adverse events.

Reference

  1. Huang Q, Li J, Sun Y, Wang R, Cheng X, Chen H. Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small cell lung cancer by a meta-analysis. Chest. 2016;149(6):1384-1392.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters